CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Graft Polymer announces plan to list on LSE

By Angela Barnes

08:45, 22 December 2021

London Stock Exchange exterior in London, UK
In 2020, the global impact modifier market was estimated to have a value of $3.9bn (£3bn) – Photo: Shutterstock

Graft Polymer has announced its intention for its stock to be admitted to the standard segment of the Official List of the Financial Conduct Authority (FCA) and to trade on the Main Market for listed securities of the London Stock Exchange.

In a statement published on Wednesday, the business outlined that it is focused on the development of polymer modification and drug delivery systems.

It said it has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing and reducing material consumption, in turn reducing costs.

In 2020, the global impact modifier market was estimated to have a value of $3.9bn (£3bn).

Patent applications

Graft Polymer said it has made several patent applications and has a layered IP strategy.

“The group’s products address customer needs across a wide range of end use markets, from automotive through to medical and is not dependent on one market segment,” it said.

In late 2018, the company said it began its first commercial sales to various polymer compounders in the automotive, packaging, construction, consumer products, clothing, aerospace, healthcare and medical markets.

“The group has licensed its Drug Delivery System (‘DDS’) platform IP to MGC Pharmaceuticals (‘MGC Pharma’) in relation to MGC Pharma’s CimetrA product. The group expects to receive royalty payments resulting from the sale of CimetrA and CannEpil-IL products,” it added.

The business currently has distribution relationships with multiple partners globally, including in Europe, India and Russia and is now seeking to accelerate its growth strategy and provide access to new sources of funds.


10.36 Price
+12.420% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.04


6.49 Price
-1.530% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.04


0.20 Price
-3.000% 1D Chg, %
Long position overnight fee -0.0253%
Short position overnight fee 0.0033%
Overnight fee time 22:00 (UTC)
Spread 0.005


0.30 Price
+16.930% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.0031

Spending plans

Graft Polymer said the funds raised will be used for an additional production line and further expansion of its research and production facility in Slovenia.

Moreover, funds from an IPO would also go towards investing in a HACCP and food grade ‘GMP’ certification at the group’s facility in Slovenia, upgrading laboratories, future IP registrations, sales and marketing, and general corporate purposes.

Admission is expected in early January 2022.

Victor Bolduev, founder and CEO of Graft Polymer, commented on the plans.

“We are delighted to be bringing Graft Polymer to the London Stock Exchange’s Main Market, particularly at a time when demand for combining polymer modification and environmental protection is rising. Graft Polymer’s IPO will provide the Company with further capital to accelerate our developing of intellectual property as well as new technologies to provide novel products and solutions for market challenges that arise.

“Led by a highly experienced management team, we believe the diversity of our products enable us to deliver to various industries, distinguishing Graft Polymer from other global polymer modification groups which offer significantly narrower products and solutions,” Bolduev said.

Appointment of advisors

The company has engaged Turner Pope Investments as its UK broker and RBG Legal Services, trading as Memery Crystal, as its UK legal adviser.

Graft Polymer also said it has retained Tavistock Communications to provide public relations services in the UK.

Read more: Rio Tinto buys Argentina-based lithium project for 5m

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading